Drugs / ATG-037
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05205109 | Jun 2022 → Aug 2027 expected | — | Antengene Therapeutics Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2026-09-14 | Antengene Corporation | Results Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG‑037 Combined with Selinexor in Cancer Gene Therapy antengene.com ↗
Selinexor treatment was found to upregulate CD73 expression in the majority of tumors, a resistance-associated mechanism that the combination approach was designed to counter. |
| 2025-05-23 | Antengene Corporation | Results Antengene to Present Latest Clinical Results from Two Studies in CPI-resistant Solid Tumors at ASCO 2025 antengene.com ↗
In CPI-resistant non-small cell lung cancer (NSCLC), the combination of ATG-037 and pembrolizumab achieved an ORR of 22% and DCR of 67% in the same study. |
| 2023-11-17 | Antengene Corporation | Results Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day antengene.com ↗
Clinical programs, including ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), and ATG-037 (oral CD73 inhibitor) have shown clinical responses in cancer patients with advanced diseases. |
| 2023-04-18 | Antengene Corporation | Results Antengene Announces Five Presentations at the 2023 American Association for Cancer Research Meeting antengene.com ↗
Results showed complete inhibition of CD73 with ATG-037, without a “hook effect” compared to another industry benchmark antibody program. |
| 2022-11-03 | Antengene Corporation | Regulatory Antengene Announces IND Approval for the Phase I STAMINA-001 Study to Evaluate ATG-037 (CD73 Inhibitor) for the Treatment of Locally Advanced or Metastatic Solid Tumors in China antengene.com ↗
ATG-037, an inhouse asset developed by Antengene and with global rights, has been approved to enter clinical studies in Australia and China, thus becoming the first oral small molecule CD73 inhibitor entering the clinical-stage in China and the wider Asia Pacific region. |
| 2022-03-09 | Antengene Corporation | Results Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting antengene.com ↗
We are very pleased to share these results with the oncology community. |
| 2022-02-07 | Antengene Corporation | Regulatory Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037 antengene.com ↗
ATG-037 has received approval by the Bellberry Human Research Ethics Committee(HREC) in Australia to initiate the Phase I STAMINA trial, a first-in-human study of ATG-037 in patients with locally advanced or metastatic solid tumors. |
All press releases naming this drug 12 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG-037 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05205109 ↗ |
| Route | Oral | “ATG-037 will be administered orally” NCT05205109 ↗ |